Trial Details
Not RecruitingBasic Information
| Clinical ID | c5430 |
|---|---|
| Identifier | ACTRN12623000234617 |
| Trial Title | A Single Center, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Dose Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics of AC-101 |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | Inflammatory Bowel Disease; Inflammatory Bowel Disease;Oral and Gastrointestinal - Inflammatory bowel disease |
| Interventions | Accro Bioscience is developing AC-101, a potent and selective oral small molecule inhibitor of RIPK2, indicated for treatment of inflammatory bowel disease (IBD). Investigational Product (IP): AC-101Dosage Form: TabletMode of Administration: O |
Participant Information
| Sponsor | Accro Bioscience (Australia) Pty Ltd |
|---|---|
| City | NULL |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |